LipoScience prices IPO at $9, 36% below original midpoint

By Renaissance Capital,

Shutterstock photo

LipoScience, which provides a diagnostic test to assess cardiovascular disease risk, raised $45 million on Thursday by offering 5 million shares at $9, 36% below the midpoint of the original $13-$15 range. The company cut its estimated price range to $9-$10 earlier on Thursday. LipoScience plans to list on the NASDAQ under the symbol LPDX. Barclays, UBS Investment Bank and Piper Jaffray acted as underwriters on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: LPDX

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by